Showing results (131-140 of 548) with videos related to
Sort By:
Pageof 55
Therapeutic Advances in Psychopharmacology|July 7, 2022
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of actionMark J MillanTherapeutic Advances in Psychopharmacology|September 14, 2020
Psychedelics and virtual reality: parallels and applicationsJacob S Aday, Christopher C Davoli, Emily K BloeschTherapeutic Advances in Psychopharmacology|May 28, 2021
Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depressionAdam Włodarczyk, Wiesław J Cubała, Maria Gałuszko-Węgielnik, et al.Therapeutic Advances in Psychopharmacology|June 23, 2021
Agomelatine for postpartum depression and breastfeedingLe XiaoTherapeutic Advances in Psychopharmacology|December 5, 2022
Classic psychedelics, health behavior, and physical healthOtto Simonsson, Peter S Hendricks, Richard Chambers, et al.Therapeutic Advances in Psychopharmacology|July 1, 2022
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysisMaximilian Huhn, Thomas Arndt, Johannes Schneider-Thoma, et al.Therapeutic Advances in Psychopharmacology|June 24, 2022
Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factorsTeodora Andric, Karl Winckel, Timothy David Tanzer, et al.Therapeutic Advances in Psychopharmacology|July 17, 2019
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxilMarjie L Hard, Angela Wehr, Lisa von Moltke, et al.Therapeutic Advances in Psychopharmacology|July 18, 2019
What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?Petr PotměšilTherapeutic Advances in Psychopharmacology|October 30, 2013
Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosisMatthias Kirschner, Anastasia Theodoridou, Paolo Fusar-Poli, et al.Pageof 55